A pilot study is currently underway at the prestigious Bollerup Horse Clinic in Sweden with strong initial results. The first 9 out of 10 horses on the study found relief from their cuffing symptoms in less than 10-15 minutes. There are currently 33 horses on the study and the plan is to have tested approximately 75 by the end of the year.  To download a PDF about this clinical study, please click below...

The use of cellulose powder to treat seasonal allergic rhinitis in humans is well documented, researched and proven...

P Josling and S Steadman, use of cellulose powder for the treatment of Seasonal Allergic Rhinitis: In this open study of over 100 volunteers the participants were asked to rate how well Nasaleze performed in comparison to pharmaceutical products they had taken in the past.

Nasaleze was working more effectively for them than some of the world’s biggest selling allergy brands such as UCB Pharma’s Benadryl anti-histamine. This study was peer reviewed and published in a US publication called Advances in Therapy Vol. 20. No 4.

V Aivazis, E Bourli, T Maratou et al, measure of improvement in nasal muco-ciliary clearance and peak inspiratory flow rate (PNIFR) in children with allergic rhinitis: This study involved 100 children with an average age of 8.2 (but including children as young as 1.5 years) and showed a significant improvement in Nasal Mucous Clearance reduced from 39 minutes to 18.15 minutes and a PNIFR improvement of up to 25.7%. Both these improvements were due to Nasaleze aiding the regeneration and normalization of the ciliary’s epithelium.

This study was published in a leading Greek Medical Journal, Nea Pediatrica Chronica; April-June 2005. Vol 5. No 2 and was presented at the 2005 European Academy of Aerbiology and Clinical Immunology in Munich.

K Vlahtsis, clinical study of Nasaleze for relief of allergy symptoms including sneezing, runny nose, itchy and watery eyes: All 40 participants in this study were using a pharmaceutical treatment (decongestants, corticosteroids and anti-histamines) for their hayfever at the beginning of this study. Participants were asked to discontinue the use of their pharmaceutical treatments and use Nasaleze only. After 3 weeks of use 85% of participants realized improvement in their allergy symptoms. After 6 weeks of use, 90% of participants realized improvement in their symptoms.

This study was presented at the Pan Hellenic Conference of ENT Specialists on 19th March 2004.

J Emberlin and R Lewis, effect of Nasaleze on symptoms of hayfever in adults and the difference in the amount of rescue medication used: In this double blind placebo controlled study of 100 adult hay fever sufferers the amount of rescue medication (including antihistamines and nasal sprays) used by the placebo group was significantly greater than that used by the active (Nasaleze) group.

This study has been peer reviewed and published in the respected UK Current Medical Research and Opinion (CMRO) 2006. Vol. 22.

J Emberlin and R Lewis, efficacy of Nasaleze for use in hay fever via pollen provocation tests: In this study involving 11 adult hay fever sufferers (diagnosed to be allergic to grass pollen by skin prick test and history of hayfever symptoms over the previous years) Nasaleze was shown to have significant effects in reducing symptoms of sneezing and itchy eyes.

This study was presented at the European Academy of Allergology and Clinical Immunology (EAACI) conference in Vienna. June 2006 by J Emberlin and R Lewis.

J Emberlin and R Lewis, double blind placebo controlled cross over challenge study by nasal provocation with house dust mite allergen 2006: The results show significant differences (p=<0.05) for sneezing, itchy nose, runny nose and ECP’s in nasal secretions. The results were also significant at this level for peak nasal expiratory and inspiratory flow but there was considerable variation. The results for other symptoms were not significantly different between the cellulose powder and the placebo. There were no adverse reactions.The inert cellulose powder can have significant effects in reducing some symptoms of persistent rhinitis due to house dust mite allergy. Presented as a Poster at the European Academy of Aerobiology and Clinical Immunology, Sweden, June 2007.

This study has been published in the UK Journal ‘Current Medical Research and Opinion’ 2006. Vol. 23 No 10.

« Back to Nostrilvet Introduction